Bartlett & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bartlett & Co’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-440	Closed	-$33K	–	432
2021 Q3	$33K	Hold	440	–	–	﹤0.01%	563
2021 Q2	$41K	Hold	440	–	–	﹤0.01%	536
2021 Q1	$39K	Hold	440	–	–	﹤0.01%	578
2020 Q4	$41K	Buy	+440	New	+$35.1K	﹤0.01%	552

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bartlett & Co's ARKG Position: Q4 2021 in Review

Bartlett & Co sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 440 shares — an estimated $33K sold.

Bartlett & Co first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $41K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

Bartlett & Co reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
Bartlett & Co sold 440 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $33K.
Bartlett & Co first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
Bartlett & Co's ARK Genomic Revolution ETF position peaked at $41K in Q2 2021.
460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Bartlett & Co's 13F filing for Q4 2021, filed 8 Mar 2022.